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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a common and important group of 
conditions characterised by airflow obstruction with related symptoms including cough, 
shortness of breath, expectoration and wheeze.  The widely accepted Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) has classified COPD as “a disease state 
characterised by airflow limitation that is not fully reversible.  The airflow limitation is 
usually both progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles or gases” (1). The current GOLD definition for airflow limitation 
is a forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) ratio of < 70% 
and disease severity is classified into four physiological stages: stage 1 (FEV1 > 80% 
predicted); stage 2 (FEV1 > 50 to < 80% predicted); stage 3 (FEV1 > 30 to < 50% predicted); 
stage 4 (FEV1 < 30 or < 50% predicted in the presence of chronic respiratory failure) (2). 
COPD is one of the foremost causes of chronic morbidity and mortality worldwide.  
Globally, it affected 44 million people in 1990 (3) and recent estimates  suggest that COPD 
affects approximately 210 million people (4) or  10% of all adults  (5) with the prevalence 
continuing to rise.  In 2007, COPD accounted for 5% of all deaths (4) but the WHO predicts 
an increase in COPD-related deaths of more than 30% in the next 10 years, emphasising the 
continued impact this disease will have internationally (6).  
Cigarette smoking remains the most important risk factor for the development of COPD (7) 
although only approximately 20% of smokers develop clinically significant disease (8).  This 
suggests that a combination of genetic and environmental factors interact to cause COPD, 
and there has been much research aiming to identify candidate genes that may confer 
genetic susceptibility.  To date, however, only deficiency alleles on the 1AT gene have been 
robustly identified as predisposing to disease (9).  
Pathologically, COPD is characterised by widespread inflammation of the peripheral and 
central airways with destruction of the lung parenchyma. Oedema, fibrosis, smooth muscle 
hypertrophy and loss of elastic recoil lead to bronchial wall thickening, which affects airflow 
(10). 
COPD, while primarily a lung disease, is associated with increased co-morbidity including 
cardiovascular disease, type 2 diabetes, osteoporosis and systemic pathology such as muscle 
wasting and dysfunction. It has been hypothesised that persistent low-grade inflammation 
may drive the co-morbidity and the systemic effects noted with this disease (11). The 
systemic manifestations of COPD are important, as they are not only associated with 
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increased morbidity, but are also predictive of disease outcome, especially Body Mass Index 
(BMI) which forms part of the BODE index (Body Mass, airflow obstruction, dyspnoea and 
exercise capacity) and is used to classify the impact of the disease (12). 
There is great heterogeneity in COPD, and disease presentation and the underlying 
pathology seen varies between individuals. Although COPD is defined by airflow 
obstruction, disease phenotypes include emphysema (defined pathologically as the 
destruction of alveolar walls and the permanent enlargement of the airspaces distal to the 
terminal bronchioles); bronchiectasis (defined pathologically as localised, permanently 
dilated bronchi and characterised by excess mucus production and reduction of mucociliary 
clearance), bronchiolitis  (inflammation of the bronchioles) and chronic bronchitis. Chronic 
bronchitis is defined clinically as the presence of chronic productive cough for at least 3 
months in each of 2 successive years in patients in whom  other causes of chronic cough 
such as tuberculosis, heart failure and carcinoma of the lung, have been excluded (13).  It is a 
feature of approximately 50% of people who smoke (14) and 30% of patients with COPD 
(15),  although air pollution, the inhalation of toxic gases and upper gastrointestinal 
pathology such as reflux disease have also been associated with the condition (16).   
Chronic Bronchitis is thought to be of special significance in COPD, as it is associated with 
increased inflammation and poorer patient outcomes.  This chapter will review the 
pathology of chronic bronchitis, its’ inflammatory basis, associated morbidity and mortality 
and potential treatments. 
2. Background 
Chronic bronchitis is common, affecting approximately 6 to 12% of adults, over 20 years of 
age. Cigarette smoke -exposure remains the most important aetiological risk factor for 
development of both chronic bronchitis and COPD (17-19).  There is a six-fold rise in 
prevalence from 6.3% in non-smokers to 40% in heavy smokers (20), with a linear 
relationship between cigarette smoke exposure and chronic bronchitis(19).  Other risk 
factors associated independently with chronic bronchitis include poor socioeconomic 
background, recurrent or severe childhood respiratory illness and exposure to 
dusty/polluted environments (18, 21).   
There is great heterogeneity between patients, and both time of presentation and disease 
course vary.   In a proportion of patients, sputum expectoration occurs without airflow 
obstruction, while in others, airflow obstruction precedes sputum expectoration (22).   There 
is some debate whether chronic bronchitis is solely a recognised phenotype of COPD, or 
whether it is an entirely independent disease process.  Certainly, while often present in 
unison, chronic expectoration and airflow obstruction behave largely as independent 
variables (23).  This is perhaps unsurprising as bronchial gland hypertrophy (seen in chronic 
bronchitis) occurs predominantly in larger bronchioles (24), whereas the dominant site of 
irreversible airflow obstruction occurs in more peripheral and smaller airways(25). 
Often, chronic bronchitis is preceded by recurrent episodes of acute bronchitis (26), and the 
frequency and severity of these acute episodes influences the rate of decline in lung 
function, patients quality of life  and the risk of death (27) (see later).        
Symptoms can be restricted to chronic sputum expectoration, or include those related to 
airflow obstruction, including breathlessness and wheeze.  Sputum expectoration varies 
between and within individuals and in individual patients, in terms of the frequency of 
cough, the volume and tenacity of sputum produced (which can alter the patients ability to 
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clear secretions effectively) and sputum purulence.  The majority of patients initially 
describe low-volume, mucoid sputum (clear to grey in colour), but as many as 30% of 
patients have airways which are colonised with potentially pathogenic bacteria, and this is 
more likely to be associated with the expectoration of purulent (green)  sputum (28).  See 
Figure 1 
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Fig. 1. The characteristics of sputum collected from patients with Chronic Bronchitis with 
either  purulent or mucoid sputum. 
Legend. Sputum samples were collected from clinically stable patients with chronic 
bronchitis.  87 had purulent sputum and 36 had mucoid sputum.  Samples were studied for 
the presence or absence of putative pathogenic bacteria (PP), bacteria were quantified in 
colony forming units/ml of sample, and classified as being above or below 1 x 107 cfu/ml, 
and neutrophils (PMN) were counted in a random viewing field on light  phase microscopy.  
Purulent sputum was consistently and significantly associated with the presence of putative 
pathogens, a higher number of bacterial colonies, and more neutrophils than mucoid 
sample. 
Modified from (29) and (30). 
Although standard definitions of chronic bronchitis only include chronic sputum 
expectoration, early descriptive series of patients found that 70% of patients had 
bronchospasm, 88% had either sporadic or constant breathlessness and “spells of sickness 
for several weeks or a few months” with infection thought to be causal in all cases (31).  The 
disease is characterised with periods of stability, interspersed with episodes of worsening 
symptoms (exacerbations).  These will be described later. 
Physical examination can be normal, but it can reveal signs consistent with COPD and 
emphysema (including evidence of hyper-inflated lung fields, peripheral and central 
cyanosis, cor-pulmonale and hyper-capnia).  Radiographic signs in pure chronic bronchitis 
are poorly documented, as the most frequently quoted studies (for example (32, 33)) did not 
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exclude patients with emphysema. However, it is likely that chest radiographs in the 
majority of patients with chronic bronchitis are normal (34), as the bronchial wall thickening 
which is characteristic of chronic bronchitis is approximately  0.1 – 0.5mm (24, 35) and 
therefore too small to be noticeable in plain x-rays.  Bronchial wall thickening can be seen on 
high resolution computer tomography scans of the thorax (36).  See figure 2. 
 
 
Fig. 2. High resolution CT image showing moderate bronchial wall thickening and mild 
bronchial dilatation in a patient with chronic bronchitis.  
Used with permission from Hochhegger et al, Imaging, 2008; 20 (37).  
There is a robust series of studies demonstrating that Chronic Bronchitis is associated with 
increased morbidity and mortality. It is an independent risk factor for all cause mortality 
both in COPD (38), and in subjects with normal lung function, even when smoking has been 
accounted for  (38-40).   The overall ten year mortality following a diagnosis of chronic 
bronchitis is 50%, with respiratory failure following an acute exacerbation being the most 
frequent terminal event (41).   
Currently there are no clearly identified genetic risk factors for Chronic Bronchitis, 
however,  twin studies have suggested that the heritability estimate for this condition is 
40%, with only 14% of genetic influences shared with those related to smoking habits (42). 
Studies of  polymorphisms of the TNF gene (which reside in the promoter region of the 
gene, are associated with increased secretion of TNF in the lung, and an increase in 
neutrophilic inflammation (43)) have shown a strong association with a chronic bronchitis 
phenotype in COPD (43, 44). However, this polymorphism has a minor allele frequency of 
4 – 6% (43), and hence, other susceptibility factors must exist.  There is currently an 
interest in genome wide association studies, and perhaps these will identify more 
potential candidate genes (45). 
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3. The pathology of chronic bronchitis 
3.1 An overview of the histological changes seen in chronic bronchitis 
Chronic bronchitis is characterised pathologically by mucus hyper-secretion with bronchial 
mucous gland hypertrophy and chronic inflammation of the bronchi and bronchioles, with a 
subsequent inflammatory cell infiltrate.   Inflammation of the bronchial epithelium  can 
produce squamous metaplasia, with a loss of ciliated cells.  The metaplastic squamous 
epithelium can become dysplastic from persistent injury by smoking, and may become 
malignant (squamous cell carcinoma of the bronchus).  Typical changes seen histologically 
with chronic bronchits are shown in Figure 3. 
 
 
Fig. 3. Histology of Chronic Bronchitis 
Legend. This figure demonstrates epithelial thickening (A), mucous gland hypertrophy and 
metaplasia (B) and prominence of airway smooth musculature (C), all of which are typical 
features in chronic bronchitis. 
The earliest abnormality in chronic bronchitis is thought to be a respiratory bronchiolitis, 
affecting airways of less than 2mm in diameter, in response to chronic cigarette smoke or 
toxin exposure.  Destruction of the airway wall and surrounding parenchymal elastin can 
lead to mural weakness and this coupled with mucus hyper-secretion predisposes towards 
bronchiolar obstruction.   
The bronchioles are so numerous, that bronchiolar obstruction must be widespread and 
extensive to give clinical symptoms and studies confirm that pathological changes are seen 
before the clinical manifestations of disease (46). Squamous metaplasia  and increased 
epithelial thickening is also seen prior to symptomatology and without airflow obstruction, 
although there is a relationship between epithelial layer thickness and COPD severity (25).  
However, all of these changes vary between patients, even in those with a similar degree of 
airflow obstruction (47).  
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Mucous gland hypertrophy and metaplasia occurs in response to inflammatory signals 
present in the airways of patients with chronic obstructive pulmonary disease (48) and 
contribute to airflow obstruction (49). Cigarette smoke-induced chronic airway 
inflammation also causes constriction and hypertrophy of airway smooth muscle cells (49) 
which become more prominent in biopsies taken from subjects with chronic bronchitis. In 
keeping with this observation, some studies have described an increase in airway smooth 
muscle mass in COPD  (50) and have associated this with increases in airway wall thickness, 
greater luminal narrowing, and increased airflow resistance with poorer clearance of 
pulmonary secretions (51). 
The inflammatory changes seen in chronic bronchitis occur in the mucosa, gland ducts and 
glands of both the intermediate sized bronchi (with an internal diameter of 2 – 4mm) and 
smaller bronchi and bronchioles (less than 2mm in internal diameter).  
3.2 Pulmonary secretions 
Airways secretions form an important component of the primary host defence system.  In 
the trachea, there are approximately 4000 submucosal glands which produce both the 
mucus (52), and important proteins such as antibacterial proteins (including lysozyme (53) 
and lactoferrin (54)), secretory component necessary for immunoglobulin (Ig) A transport 
(55), and the antiproteinase, secretory leukoprotease inhibitor (SLPI) (56).  Submucosal 
glands are composed of a central acinus consisting of serous cells, and a tubule lined with 
mucous cells. Plasma cells (responsible for the production of IgA) are also found in the 
submucosal glands (57). 
The serous and mucous cells of the bronchial glands secrete the majority of the bronchial 
secretions, although goblet cells, and both the serous and clara cells of the airway epithelium 
make important contributions.  Secretions are further diluted by alveoli surfactant and 
plasma fluid transudate (58).   Bronchial mucus is composed of  a continuous watery sol 
layer which overlays the bronchial epithelium and in which the cilia beat; and a more 
viscous gel layer, which lies on the tips of the cilia.  The sol layer is 5 - 10m deep, and is 
derived from the clara cells in the airway epithelium at the bronchiolar level with some 
contribution from fluid transudation. The sol layer enables the cilia to propel the gel layer 
over its surface, and is fundamental to mucociliary clearance.  The mucus gel layer is 
derived from several sources including goblet and serous cells in the airway epithelium, 
clara cells at the bronchiolar level (59) and the submucosal glands (60).  The sol phase 
contains soluble bronchial proteins and serum proteins, whilst the gel phase contains the 
mucinous glycoproteins, other serum proteins and also proteins bound to mucins (61).    
Bronchial mucus has many functions.  It reduces evaporative loss from the respiratory tract, 
provides a protective barrier over the bronchial epithelium and removes trapped inhaled 
particles via ciliary action.  The mucus also provides a medium for immunoglobulins and 
other protective proteins. 
In healthy individuals, airway secretions are moved up to the mouth by ciliary action in the 
mucociliary escalator. Ciliated cells are found primarily in the tracheo-bronchial epithelium, 
although they are also present in the bronchioles (60, 62).  There are approximately 200 – 300 
cilia per cell; each is 4 – 6 m long and 0.1 – 0.2 m in diameter.  The cilia beat 1000 times per 
minute, and in health the action of the cilia is co-ordinated, both within a single cell and 
between adjacent cells (63). The ciliary beat cycle has two components. The first is 
movement towards the larynx; this is the effective stroke, and is followed by a recovery 
stroke in the opposite direction where the cilia bend and disengage from the mucus (64).  
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Microvili project between the cilia and are believed to regulate the depth of the periciliary 
fluid level. 
The clearance of mucus depends on ciliary action (65), cough, mucus volume, and the 
viscoelasticity and adhesiveness of the mucus to the airway epithelium.  Mucus 
transportation has two phases, a fast phase related to ciliary clearance and cough, which is 
completed after a few hours in healthy individuals, and a slower phase which represents 
alveolar clearance and occurs over weeks or months (66, 67). 
Mucocilary clearance is impaired in chronic bronchitis.  There are many reasons for the 
impairment, including inhibition of ciliary activity by proteinases such as neutrophil 
elastase (NE) released from neutrophils recruited to the lungs (68), the presence of bacterial 
products (69) and epithelial damage. In chronic bronchitis, the inflammatory exudate 
overwhelms the normal clearance mechanisms, and the excess and accumulated secretions 
are expectorated in the form of sputum, which is a mixture of bronchial secretions, cells, 
cellular debris, cleared organisms and saliva, resulting in the chronic productive cough that 
characterises chronic bronchitis. 
Mucinous glycoproteins are synthesised in mucus and goblet cells. Activated transcription 
factors upregulate expression of MUC genes in the nucleus of these cells. New MUC 
transcripts are translated to MUC proteins on ribosomes and cotranslationally inserted into 
the endoplasmic reticulum (ER). Glycosylation of the MUC protein backbone is initiated 
post-translationally in the cis-Golgi. Mature  (fully glycosylated), mucins are packaged and 
stored in secretory granules until a mucin secretagogue triggers mucin secretion at the 
apical surface of the cell (70).   
Airway mucins are overproduced by patients with chronic airway diseases like chronic 
bronchitis/COPD. This sustained mucin secretion, requires increased biosynthesis of 
mucins to replenish secretory granules, which in turn necessitates upregulation of MUC 
genes. Eight MUC genes (MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8 and 
MUC13) are expressed in normal respiratory tract tissues (70), and although they are basally 
active in order to maintain mucin release to promote muco-ciliary clearance, protein 
transcription can be up-regulated dramatically in inflammation and infection. 
In Chronic Bronchitis, a number of factors have been shown to up-regulate MUC genes, 
including neutrophil elastase, a proteolytic enzyme stored within neutrophil granules (see 
later). Inflammatory mediators have also been implicated, including IL-8 (71) and LTB4 (72) 
and oxidative stress (73).  It is hypothesized that the on-going inflammation, intermittent 
infection and viral and bacterial colonization that is present in some patients with chronic 
bronchitis leads to excessive MUC gene activation, mucin production and goblet cell 
hypertrophy.  If these genes were amenable to modulation, they would be a potential 
therapeutic target in the treatment of this disease. 
3.3 Immunology and inflammation in chronic bronchitis 
The inflammatory response seen in the lungs of patients with chronic bronchitis is complex, 
involves the innate and acquired immune system and serves as a self-perpetuating stimulus 
for further immune activation.  Cigarette smoke exposure is the most important risk factor 
for developing chronic bronchitis, but the symptoms, the inflammation and the decline in 
lung function parameters continue, even after smoking cessation (74, 75). 
Chronic Bronchitis is associated with the recruitment of leucocytes into lung tissue, the 
production of inflammatory mediators and the release of destructive proteins into the 
milieu, including proteinases.  Bronchial biopsies taken from patient with chronic bronchitis 
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show an increase in inflammatory cells compared with non-smokers and smokers with no 
symptoms of chronic mucus production (10).  The cellular composition varies between 
individuals, but typically includes neutrophils, macrophages and CD8+ T cells.  There are 
also smaller numbers of CD4+ T cells, but these may be monoclonal (76), and limited to 
pulmonary follicles (77).   
Consistently, research has highlighted the importance of the neutrophil in the pathogenesis 
of COPD and chronic bronchitis.  Patients with chronic bronchitis and COPD have increased 
numbers of neutrophils in proximal airway secretions (78, 79) and broncheoalveolar lavage 
fluid (BALF) (80) compared with asymptomatic smokers, and numbers increase with 
increasing disease (81, 82).  Airway neutrophil numbers are also raised in patients with 
chronic bronchitis without COPD, although less so than when airflow obstruction is present 
(83). Sputum neutrophilia is associated with a faster decline in FEV1 compared with those 
with lower neutrophil counts, losing approximately 1% more than predicted each year (84) 
and neutrophil counts decline with smoking cessation (85), consistent with the benefits of 
this intervention. 
The neutrophil is the most abundant circulating leukocyte.  The average peripheral blood 
neutrophil count is 2.5 – 7.5 x 106 /ml and when inactive, its’ circulating half life is only 6 – 8 
hours, which means that the bone marrow is required to produce and release more than 5 – 
10 x 1010 neutrophils daily, with the capacity to increase production further if needed. 
Exposure to cigarette smoke appears to stimulate neutrophil differentiation and maturation, 
causing a peripheral leucocytosis (86, 87) which has been found to correlate with the 
severity of airflow obstruction (88). Fully mature neutrophils leave the bone marrow in a 
non-activated state and have a half life of 4 to 8 hours before marginating and entering 
tissue pools (89). Once in tissue, neutrophils are usually removed by apoptosis leading to 
their recognition and phagocytosis by macrophages in the main and by other neutrophils 
when the macrophage clearance system is overwhelmed (90).  This mechanism prevents cell 
necrosis and the release of the remaining cellular content of proteinase and other mediators.  
Neutrophils migrate into the lung in response to soluble pro-migratory stimuli, which 
include non-chemotactic cytokines (such as TNF and IL-1), chemotactic cytokines 
(chemokines including Interleukin 8) or chemoattractants (such as Leukotriene B4, (LTB4) 
and Complement factor C5a). Neutrophils are present at both the bronchial and alveolar 
level in chronic bronchitis and COPD, and therefore it is likely that neutrophil migration 
occurs from both the bronchial and pulmonary circulation.  
In the bronchial circulation, neutrophils appear to migrate from vessel to tissue in a step-like 
process, dictated by the sequential activation of adhesive proteins and their ligands on 
neutrophils and endothelial cells. Migration begins with the capture of neutrophils from 
flowing blood, causing the cell to roll along the endothelial surface. Tethering and rolling of 
the neutrophil along the vessel wall is a normal feature of circulating neutrophils and is due 
to reversible binding of transmembrane glycoprotein adhesive molecules called “selectins”, 
which are found both on neutrophils and endothelial cells (91). The next step in neutrophil 
migration is the transition from reversible rolling to firm adhesion with the endothelium. 
This is achieved by the sequential activation of  neutrophil receptors called Integrins  (92, 
93). The final step of neutrophil recruitment from the bronchial circulation to the lungs is 
transendothelial migration.  This is believed to occur preferentially at tricellular junctions 
(94), requiring the activation of Platelet endothelial cell adhesion molecule (PECAM1) (95) 
which is distributed evenly around the neutrophil and at intercellular junctions of 
endothelial cells. Once through the endothelial cell layer, leukocytes bind to matrix 
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components such as collagen and laminin via ß1 integrins, with VLA-6 and 9 being perhaps 
the most important in allowing neutrophils to move through venule basement membrane 
and lung tissue (96-98).  See figure 4.  After this step, the neutrophil may come in close 
contact with the sub-mucosal glands and mucus containing epithelial cells.  This is 
associated with mucus emptying from cellular tissues via a proteinase/ epidermal growth 
factor axis (73). 
 
 
Fig. 4. Schematic summary of Neutrophil and Endothelial Cell Adhesion Molecules and 
their ligands in neutrophil transendothelial migration. 
Legend. A: Early but short lived binding between L-Selectin and it’s ligand initiates 
transient rolling on the endothelium surface.  B. Interactions betweem P selectin and PSGL-1 
and E-selctin and ESL-1 slows neutrophil rolling and allows transient tethering.   C. Firm 
adhesion occurs through integrins and ICAM-1 associations. D. PECAM-1 interactions allow 
homing to intracellular junctions and diapedis via 1 Integrins. 
Neutrophils are capable of sensing and migrating to sites of  inflammation by sensing 
chemotactic gradients formed by pro-inflammatory stimuli. Neutrophils migrating within 
the lung encounter multiple chemoattractants signals in complex spatial and temporal 
patterns as endothelial, epithelial cells and immune cells respond to infection or injury, 
releasing a cocktail of cytokines and chemokines. In vitro models have demonstrated that 
neutrophils can migrate up and down chemical gradients, responding to one signal, 
migrating to its concentration peak and then migrating up a novel, more distant 
chemoattractant gradient, from endothelium to tissue (99).  Thus the size and source of the 
gradient will influence any affect of neutrophils on mucus production. 
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Once neutrophils have migrated to the source of inflamed and infected tissue, their role is to 
kill and remove micro-organisms.  The neutrophil achieves this by a process of phagocytosis, 
the respiratory burst and the release of cytotoxic peptides and proteins. These proteins include 
proteinases, which are bactericidal. Neutrophil elastase (the most well-studied of the 
proteinases) can break down the Outer membrane protein A (OmpA) of E. coli and other 
Gram-negative bacteria, and  break down Shigella virulence factors, by cleaving peptide bonds 
in target proteins including small, hydrophobic amino acids such as glycine, alanine, and 
valine (100). Other cytotoxic peptides include the human neutrophil peptides 1 – 4 (collectively 
known as “the defensins”) which account for 50% of the total protein content of azurophil 
granules and are highly toxic to fungi, enveloped viruses and bacteria (89).     
Defensins also enhance mucin production by activating MUC gene transciption (101). 
Neutrophil proteinases are usually released in a controlled intracellular environment, by 
fusing phagasomes (lipid membrane enclosed vesicles containing engulfed bacteria) with 
lysosymes (vesicles containing proteinases and oxidants).  However, if proteinases are 
released from the cell into the extracellular matrix, they have the potential to be extremely 
destructive.   Neutrophil elastase is capable of degrading all components of the extracellular 
matrix (ECM) by cleaving peptide bonds, including elastin, fibronectin and collagen, 
causing structural damage to tissue and airways (102).  
Neutrophil elastase release is thought to be an important driver of disease pathogenesis in 
chronic bronchitis (28), and occurs during neutrophil migration, phagocytosis and cell 
death.  Indeed, elastase is the most potent secretogogue studied to date.   When neutrophils 
migrate through the ECM, it is known that a high proportion of neutrophil proteinases are 
expressed on the neutrophil membrane (103-105), polarising towards the leading edge of the 
neutrophil (106). A proportion of the proteinase is left behind as the cell moves on (106, 107) 
and it has been clearly demonstrated that an area of obligate elastase activity (or “collateral 
damage”) always exists following the secretion of free proteinase from activated neutrophils 
until concentrations have decreased by diffusion to match the concentration of surrounding 
proteinase inhibitors (108, 109).   See Figure 5.  Neutrophil proteinases are released during 
degranulation, and phagocytosis (“sloppy eating”), especially during “frustrated 
phagocytosis”, when cells attempt to ingest large particles (110).  In contrast with apoptotic 
cells, proteinases are released during cell necrosis (111) and finally, proteinases can be 
released from activated macrophages, which scavenge the proteinases from apoptotic 
neutrophils via endocytosis and subsequently release them during the first 24 hours of their 
own inflammatory response (112). 
As well as degrading lung tissue, neutrophil proteinases have many other effects in chronic 
bronchitis and COPD. When released from neutrophils, they damages the respiratory 
epithelium, reducing ciliary beating (68, 113) and triggering a state of oxidative stress in 
cells (114). Proteinases can induce apoptosis of epithelial cells  (115) and detachment of 
bronchial epithelial cells from the extra cellular matrix (116), which is thought to be 
important in COPD and chronic bronchitis (117).  Proteinases  stimulate the release of other 
pro-inflammatory signals such as LTB4 by macrophages (118) and IL-8 from bronchial 
epithelial cells which enhances more neutrophil migration into the lung. Proteinases also 
decrease the function of immunoglobulins and activate components of the complement 
cascade (119, 120) and may also effect wound healing, by effecting transforming growth 
factor β and the epithelins (121).  The inflammatory consequences of neutrophil proteinases 
on lung tissue and cells relevant to the development of chronic bronchitis and COPD are 
summarised in table 1.   
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Fig. 5. The potential mechanism for tissue damage during extracellular proteinase release 
from neutrophils 
Legend. As neutrophils migrate towards a source of inflammation, granules containing 
proteinases including neutrophil elastase (NE) are mobilised towards the leading edge of 
the cell (A). These proteinases are thought to be released during migration through complex 
media (such as the extracellular matrix (ECM)) to allow a path to be made for the 
neutrophil.  Upon exocytosis, NE has a concentration of 5mM.  Alpha-1 anti-trypsin (A1AT) 
(an anti-proteinase and inhibitor of NE) is thought to be present in the interstitium at 
concentrations which are 200 times lower than NE when it is first released from a granule, 
and since the inhibitor inactivates NE on a one molecule to one molecule basis, the 
proteinase remains active. NE concentrations decrease by diffusion (represented by the dark 
green to pale green graduated circles) and it is only when concentrations have reduced to 
approximately 24uM that NE can be fully inhibited by A1AT (B).  This leads an obligate area 
of proteolysis around the leading edge of the cell, theoretically aiding the cell’s 
transmigration, and potentially leaving damaged ECM behind the cell (C).  
Although neutrophils are clearly associated with chronic bronchitis, it is likely that many 
immune cell populations are involved in the pathogenesis of this disease. Interestingly, 
there are few differences in the cellular content of bronchial biopsies taken from patients 
with COPD with and without chronic bronchitis (122) although one study has suggested a 
predominance of eosinophils in airway secretions when chronic bronchitis is present (123), 
however this observation has not been replicated.  The numbers of CD8+ lymphocytes in 
bronchial tissue relate inversely with FEV1 (122)  and have been shown capable of causing 
lung tissue damage both by their own cytotoxicity and by recruiting macrophages by 
secreting IFN-. Macrophages are the most abundant cell recovered in bronchoalveolar 
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lavage in patients with chronic bronchitis and COPD, and numbers also correlate with 
disease severity (124, 125). These cells are believed to participate in tissue damage by the 
release of their own proteinases, such as MMP-12 (although they are less potent than 
neutrophil elastase) and reactive oxygen species.   Whether macrophage proteinases 
stimulate mucus production and release is unknown.  Certainly, more studies are needed to 
fully understand and identify  pivotal inflammatory signals or biomarkers which could 
differentiate those smokers who are at most risk of chronic bronchitis and COPD, those who 
are most likely to experience frequent exacerbations of their symptoms and those at risk of 
bacterial colonisation of their airways, as these disease features are related to worsening 
clinical outcomes.   
 
Bacterial Killing 
Intra-cellular :  bactericidal following engulfment of 
organisms in phagosome 
Extra cellular: Targeting and cleaving bacterial virulence 
factors in released granule proteins 
Induces Inflammatory Cell 
migration 
NE/alpha 1 antitrypsin complexes  
are chemotactic for neutrophils 
Modification of ICAM1 expression enhancing adhesion 
Degradation by proteolysis 
Degrades all components of Extracellular Matrix  
Degrades Cystatin C 
Degrades inhibitors  of proteinases  
Cleaves T Lymphocyte surface antigen 
Activation of proteinases by 
post-transcriptional 
modifications 
Activates  proteinases including MMP-2, MMP-3, MMP-9, 
and Cathepsin B 
Modification of inflammatory 
mediators, enhancing 
inflammation 
Enhances epithelial secretion of IL8 
Enhances macrophage secretion of LTB4 
Inhibits cellular response to inhibitors of inflammatory 
mediators, for example,  TNFsR1 
Prolongs the half life of  inflammatory mediators 
including TNF  
Increases alpha1-AT expression by monocytes and 
alveolar macrophages 
Enhances Cell Apoptosis 
Increases epithelial and endothelial  
cell apoptosis 
Alteration of Cell function 
Disruption and detachment of epithelial cells 
Reduces ciliary beating of columnar epithelium    
Enhances oxidative stress    
Increases mucin production 
Increases bacterial adherence and colonisation on the 
epithelium 
Table 1. An overview of the inflammatory consequences of neutrophil proteinases thought 
relevant to the development and progression of Chronic Bronchitis and COPD. 
Legend. References are included in the text. 
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4. Bacterial colonisation in chronic bronchitis 
Approximately 25% of patients with chronic bronchitis have pulmonary secretions from 
which potentially pathogenic bacteria are cultured, even when they are clinically stable.  
These patients are deemed to have airways that are colonised with bacteria  (126).  The most 
common bacteria cultured in clinically stable patients are Haemophilus influenzae, 
Streptococcus viridans and Streptococcus pneumoniae (127) although Neisseria species and 
Proteus mirabilis have also been isolated.  Interestingly, these bacteria have been cultured in 
lower airway secretions despite the presence of antibodies in serum and sputum against the 
bacterium (128) and despite courses of appropriate oral antibiotics  (129), which suggests 
that when established, colonisation is difficult to eradicate. 
Identified risk factors for colonisation include behavioural factors such as current smoking 
(127, 130),  and repeated bacterial infections in the form of  exacerbations (see later).  
Cigarette smoke exposure is known to effect lower airway mucociliary clearance by 
reducing ciliary beat frequency (131) and the neutrophilic inflammation present in chronic 
bronchitis has been shown to be conducive to bacterial colonisation (132). Colonisation is 
associated with increased sputum concentrations of inflammatory mediators including IL-8, 
LTB4 as well as neutrophil elastase (30).  Lower airway bacterial colonisation in the stable 
state appears to increase the frequency and alter the character of COPD exacerbations (with 
patients with Chronic Bronchitis experiencing more exacerbations) (133). Exacerbation 
frequency relates to subsequent decline in lung function (134) and health status (135); 
suggesting that colonisation may be important in disease progression, although it does not 
directly relate to decline in FEV1 (127). 
The numbers of bacteria present may also alter immune cellular responses which could 
impact on subsequent inflammation, as patients with sputum bacterial loads of > 106 cfu/ml  
have been shown to have a  more robust inflammatory response than those with bacterial 
loads that are lower (30).  In animal models, bacterial loads of less than 105 organisms can be 
eradicated by macrophages and other components of the innate host defence without 
inducing much inflammation.  In patients with chronic bronchitis, a load of this magnitude 
can co-exist without secondary inflammation perhaps because a balance between bacterial 
killing and replication controls the situation. However, greater bacterial loads require 
neutrophil recruitment and the involvement of the secondary acquired immune response 
(136). Macrophages and dendritic cells facilitate bacterial clearance in a variety of ways.  
They are able to migrate to the bronchial lymph nodes, particularly to the T cell paracortical 
areas (137) where the antigen they carry is available for primary stimulation of the T cell 
clones. T cell derived cytokines then amplify the effector function of macrophages by 
enhancing their phagocytic and anti-microbial capacity (138). 
5. Exacerbations of chronic bronchitis 
Chronic Bronchitis is characterised by periods of disease stability punctuated by exacerbations. 
Several different definitions of exacerbations exist (for example (139, 140)) but a common 
definition is a subjective increase from baseline of one or more chronic symptoms including 
cough frequency, sputum production or sputum purulence and breathlessness (27). The 
episodes can be defined by severity or aetiology (bacterial, viral, environmental or unknown).    
Approximately 30% of exacerbations are thought to be caused by viral infections (141) with 
30% of these being caused by influenza, 25% by parainfluenza, 20% by rhinovirus and 15% 
by coronovirus (27).  In exacerbations requiring ventilatory support, only 15% of cases were 
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associated with positive identification of a viral pathogen, and half of these were also 
associated with a concomitant bacterial infection, suggesting that viruses are less important 
in more severe exacerbations (142).    
Pathogenic bacterial organisms are found in 50 – 80% of patients during exacerbations (143, 
144), with the most common organisms being Streptococcus pneumoniae, nontypable 
Haemophilus influenzae and Moraxella catarrhalis (19, 145).  Less frequently, gram negative 
organisms are isolated, including pseudomonas aeruginosa (146).  Previously there was 
controversy as to whether bacteria isolated from sputum during exacerbation were truly 
causative, or whether they represented colonization.   However, recent studies have 
demonstrated that mean bacteria colony forming units per ml of sample  (counted during 
quantitative sputum culture) are at least a log higher in exacerbations compared with those 
seen in the stable state (27). Further more, bacterial exacerbations such as these are 
characterized by a significant increase in pulmonary inflammation including neutrophil 
recruitment and can be identified by the presence of purulent sputum (147) which resolves 
with resolution of symptoms (148).   
Examination of sputum purulence is a simple and accurate way to differentiate between 
bacterial and non-bacterial exacerbations of chronic bronchitis (29), and can be used to 
rationalize antibiotic therapy to target those patients likely to benefit, and to protect others 
from unnecessary antibiotic exposure and potential side effects. 
Exacerbation frequency appears to increase with decreasing FEV1 and the presence of chronic 
bronchitis, but in patients with moderate to severe disease, the median exacerbation frequency 
is 2 -3 per annum  and patients with more frequent exacerbations experience a faster decline in 
FEV1 (134).  There is also a correlation with the degree of airflow obstruction and the type of 
bacteria isolated from sputum during acute exacerbations of Chronic Bronchitis and COPD, 
with Pseudomonas species and Enterobacteriaceae being predominant in patients with an 
FEV1 < 35% of the predicted value (149) although it is difficult to ascertain whether the bacteria 
are the cause or  a consequence of reduced lung function.    
Exacerbations are a significant cause of morbidity and mortality, with increasing 
exacerbation frequency being related to worsening patient outcomes, reduced exercise 
capacity and a reduced quality of life (150). Exacerbations remain the commonest precipitant 
of death and even after an exacerbation resolves, respiratory, physical, social and emotional 
impairment may persist for prolonged time (150).   The decline in health status is thought 
to be the result of prolonged periods of heightened pulmonary inflammation, with more 
immune cell recruitment to the lungs, more proteinase release, and more tissue damage 
(151).  Preventing exacerbations and treating them expeditiously is a priority in order to 
slow disease progression. 
6. Established and emerging therapies in chronic bronchitis 
Treatments for chronic bronchitis have focused upon improving or reducing sputum 
clearance and treating airflow obstruction, when present.  Airflow obstruction  is treated in 
accordance with guidelines for the treatment of COPD, and these will not be covered here.   
6.1 The treatment of exacerbations of chronic bronchitis 
During clinical exacerbations of chronic bronchitis and COPD, studies have demonstrated 
that oral prednisolone (continued for 10 days) is efficacious, improving dyspnoea, 
increasing improvements in FEV1 and increasing the time until the next exacerbation (152).    
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Results from trials of antibiotic treatment during exacerbations have been more confusing, 
as they have often not proved clinically effective (for example, (153, 154)). However, these 
trials have often been limited in their design, as they have not differentiated between 
bacterial exacerbations (where one would expect an improvement in clinical outcomes 
following appropriate treatment) and non-bacterial exacerbations (where antibiotics should 
not effect outcomes). Antibiotics are an appropriate therapy for suspected bacterial 
exacerbations, and should be reserved for patients with symptoms and signs consistent with 
infection, in the presence of purulent sputum (30, 147).  Given the bacteria isolated from 
sputum during exacerbations (see earlier), an appropriate choice of antibiotic includes broad 
spectrum penicillins such as amoxicillin (155), tetracyclines such as doxycyline (156) and 
quinolones and macrolides where allergies and bacterial resistance are important 
determinants of anti-bacterial choice .   International guidelines for treatment choice have 
not altered in the past ten years and the majority of guidelines suggest that an initial sputum 
culture is only required prior to treatment initiation when resistance is suspected.   
Salbutamol and ipratropium have been shown to improve symptoms of breathlessness and 
wheeze during exacerbations of chronic bronchitis and COPD, and increase FEV1 (157), and 
these therapies are routinely used where these symptoms predominate.  Both appear 
equally efficacious and while only a select group of patients benefit from both therapies in 
unison, side effects are minimal, supporting their use (158).  Delivery device (nebulised or 
via an inhaler) does not effect outcome (159).  It is less clear if they are beneficial in the 
absence of chronic airflow obstruction, as studies have shown mixed results (160). There are 
currently no published studies which support the use of long acting Beta2 agonists or anti-
muscurinic medicants during acute exacerbations of chronic bronchitis.   
A meta-analysis of 23 trials suggested that mucolytics also reduce symptom scores, days of 
illness and increase time until next exacerbation in chronic bronchitis (161) supporting their 
use in patients with frequent exacerbations. 
Not all patients respond to therapy, and a poorer response (with increased risk of death) is 
more commonly seen in patients aged over 65 years, those with significant co-morbidities, 
significant airflow obstruction (FEV 1 < 50% predicted) and more than 4 exacerbations per 
year (139).  Patients fulfilling these criteria should be assessed carefully to ensure that 
treatment, where needed, is started promptly.  In order to facilitate this, many patients are 
now being managed in the community with prophylactic antibiotics and oral 
corticosteroids, as it has been shown that early intervention is associated with better clinical 
outcomes (162). 
6.2 Treatments for stable disease 
Most studies of potential treatments used in chronic bronchitis have not differentiated 
between chronic bronchitis and COPD, and therefore results should be interpreted with 
caution. Certainly, patients with mild symptoms and infrequent exacerbations may not 
necessitate regular pharmacotherapy and no treatments (apart from smoking cessation) 
have been shown to reduce symptoms and alter progression or the development of airflow 
obstruction. In light of this, all patients should be encouraged and supported with 
appropriate pharmacotherapy to stop smoking, as this has clear health benefits and has been 
shown to reduce disease progression. 
Inhaled corticosteroids are a common treatment in COPD, and recommended for patients 
with a FEV1 less than 50% predicted or in patients who experience frequent exacerbations.  
Studies of inhaled corticosteroids in chronic bronchitis without airflow obstruction are 
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limited, and contradictory.  Llewellyn-Jones et al, saw a reduction in the chemotactic activity 
of lung secretions with reduced neutrophil activity in sputum from patients with chronic 
bronchitis and emphysema (163), however, other authors have not shown a similar response 
in short term trials (164). Furthermore, a three year trial of inhaled budesonide in mild and 
moderate COPD did not show any benefit in lung function decline, symptom scores or 
exacerbation rates, questioning the role for inhaled steroids in the absence of severe airflow 
obstruction (165).  Similarly, there is no clinical evidence to support the use of 
bronchodilators in chronic bronchitis in the absence of airflow obstruction, however, long 
acting 2 agonists have been shown to increase ciliary beat frequency, which could enhance 
sputum clearance (166).     
Phosphodiesterase 4 (PDE4) inhibitors are effective anti-inflammatory agents in animal 
models and have been shown to reduce inflammation in COPD and chronic bronchitis (167). 
PDE4 hydrolyzes cyclic adenosine monophosphate (cAMP) to inactive adenosine 
monophosphate (AMP). Inhibition of PDE4 blocks hydrolysis of cAMP thereby increasing 
levels of cAMP within cells.  Increases in the intracellular levels of cyclic AMP can reduce 
the activation of a wide range of inflammatory and lung resident cells (168).   
There have been trials of PDE4 inhibitors in COPD (169-171), that have confirmed a modest 
but significant improvement in spirometry in COPD, and quality of life scores and a reduction 
in the number of exacerbations experienced. There is  evidence that Roflumilast may be 
particularly beneficial in patients with COPD and chronic bronchitis (172), but it is unclear if 
this drug is effective in chronic bronchitis without airflow obstruction, and further trials are 
awaited.  PDE4 inhibitors appear to reduce the number of neutrophils recruited to the airways, 
with a reduction of between 30 – 50%, which could explain their clinical efficacy (168).  
N-acetylcysteine is both  a mucolytic and an anti-inflammatory and antioxidant drug (173, 
174).  It is widely prescribed for the treatment of chronic bronchitis in mainland Europe 
(175) and studies have confirmed that it is effective in reducing the risk of exacerbations and 
improves symptoms of chronic bronchitis (reducing sputum volume) (176).  The use of other 
mucolytics including carbocysteine, have been reviewed in a recent Cochrane publication 
(177) of 28 trials.  This review surmised that regular use of mucolytics  reduced exacerbation 
frequency and days of disability during exacerbations in patients with chronic bronchitis, 
however, this benefit was not seen in patients taking regular inhaled corticosteroids.  The 
authors suggest that oral mucolytics are a potentially useful treatment in patients with 
frequent exacerbations who are not on inhaled corticosteroids(177). 
Prophylactic antibiotics have been used in patients with stable chronic bronchitis in an 
attempt to treat bacterial colonisation, and reduce associated inflammation.   There have 
been few trials examining the efficacy of this, however a meta-analysis of 9 trials suggested 
that antibiotics reduced the days of illness experienced due to exacerbations of chronic 
bronchitis, without reducing actual exacerbation frequency (178).   Erythromycin has been 
shown to reduce exacerbation frequency in patients with chronic bronchitis and COPD (179) 
and clarithromycin has been shown to reduce the development of emphysema in smoke-
exposed mice (180).  These actions are thought to be mediated via the macrolides effect on 
matrix metalloproteinase 9 secretion (a proteinase) and are separate from the anti-microbial 
properties of the drugs (181).  Further trials are needed to assess the longterm impact of 
macrolide therapy in chronic bronchitis. 
If chronic bronchitis is caused and perpetuated by neutrophilic inflammation, one would 
expect that therapies which decrease the inflammatory response would improve clinical 
outcomes. Unfortunately, neutrophilic inflammation (as seen in COPD and chronic 
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bronchitis) is, in the main, resistant to the generic inflammatory treatments employed in 
other respiratory conditions, such as asthma and new therapeutic strategies are urgently 
required. It may be that there is no single treatment that is effective in all patients with 
chronic bronchitis, and perhaps as more is learned about its genetic and environmental 
drivers, more specific treatments for subsets of patients will be developed (practicing 
pharmacogenetics).  Until that point, there are no clear therapeutic options for patients with 
stable disease without airflow obstruction, and no treatments that prevent the decline in 
FEV1 in patients with airflow obstruction.  Current best practice includes the prompt 
treatment of exacerbations, coupled with smoking cessation support.    
7. Conclusion  
Chronic bronchitis is a common and debilitating feature of COPD, which effects between 8 
and 12 % of adults globally and despite improvements in air quality in developed countries, 
it’s prevalence has not fallen. The main risk factor for developing chronic bronchitis is now 
chronic cigarette smoke exposure, but environmental air quality remains an important  
contributing factor in the developing world. 
Chronic bronchitis is associated with bronchial inflammation, and although the neutrophil 
and its products have been shown to cause all of the pathological features of disease in vitro, 
many other cell types have been implicated in its pathogenesis.   
In COPD, the presence of chronic sputum expectoration is associated with worse clinical 
outcomes than those without. The inflammatory burden is higher in patients with chronic 
bronchitis compared with matched patients without (182) and chronic mucus hyper-
secretion is consistently associated with both an excess FEV1 decline, an increased risk of 
subsequent hospitalization (183) and death from respiratory infections (184). 
Despite it’s importance in terms of  prevalence, morbidity and mortality, chronic bronchitis 
remains under-investigated and poorly treated.  No medicants have been shown to robustly 
improve symptoms, decline in FEV1 or exacerbation frequency. The mainstay of treatment 
remains smoking cessation and prompt treatment of exacerbations. New therapeutic 
strategies are urgently required.    
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airways original research from different experts in the field.
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